Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study

Yahata, Kensei; Seta, Koichi; Kikuchi, Yūko; Koizumi, Mitsuteru; Murata, Maki; Wada, Hiromichi; Murakami, S.; Ohishi, Masanori; Tsuji, H.; investigators, Kyoto Fushimi Renal Anemia study

doi:10.1007/s10157-019-01767-w

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, practice points out that western medicine still has certain shortcomings in the healing of non-diabetic stage 4 CKD, such as poor compliance and adverse reactions in patients taking long-term medication. [ 17 , 18 ] Traditional Chinese medicine has no targeted record, but it has also accumulated some experience in the healing of CKD. [ 19 ] Traditional Chinese medicine believes that CKD is mostly caused by the dysfunction of the zang-fu organs, causing water dampness and phlegm to form congestion, which damages the kidney.…”

Section: Discussionmentioning

confidence: 99%

Retrospective study on the effect of Niaoduqing particles on outcome of non-diabetic patients with stage IV chronic kidney disease

Wei,

Li,

Han

et al. 2024

Medicine

View full text Add to dashboard Cite

This study was to investigate the improvement value of Niaoduqing particles in the outcome of non-diabetic patients with stage IV chronic kidney disease (CKD). The non-diabetic patients with stage IV CKD who were to receive Niaoduqing particles were set as the study group (252 cases), and the patients with the same disease who only received Western medicine in the public database were set as the control group (220 cases). The follow-up visits were 3 months/time for 1 year. Deaths due to various causes, doubling of creatinine levels, and end-stage renal disease were used as hard end points to stop follow-up. The clinical indexes of the 2 groups were observed and compared. The results showed that the rate of compound outcome was significantly lower in the study group (28.17%) than in the control group (36.82%), the glomerular filtration rate was significantly higher than that in the control group, and the levels of uric acid and urea were significantly lower than that in the control group (P < .05). Niaoduqing particles can reduce creatinine and urea nitrogen, stabilize renal function, delay dialysis time, and improve the incidence of compound outcome in patients with non-diabetic stage IV CKD, which is worthy of clinical promotion.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective study on the effect of Niaoduqing particles on outcome of non-diabetic patients with stage IV chronic kidney disease

Wei,

Li,

Han

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…The range of monthly treatment/management costs associated with CKD‐related anaemia has been estimated at 4654 JPY to 45 365 JPY, with costs primarily driven by treatment with an ESA and hospitalisations 7 ; these results were primarily based on patients who received dialysis and may not be reflective of the non–dialysis‐dependent (NDD)‐CKD population. Information regarding treatment patterns specific to patients with NDD‐CKD is scant and primarily derived from smaller studies 4,10 …”

Section: Introductionmentioning

confidence: 99%

“…Information regarding treatment patterns specific to patients with NDD-CKD is scant and primarily derived from smaller studies. 4,10 It has been suggested that despite the advent of long-acting ESAs, treatment rates and associated renal outcomes have been suboptimal in this population. 10 Larger database studies are needed to understand the burden of anaemia and treatment patterns among patients with NDD-CKD, which would enable a more complete understanding of outcomes in this population and facilitate more robust economic modelling studies.…”

Section: Introductionmentioning

confidence: 99%

“…4,10 It has been suggested that despite the advent of long-acting ESAs, treatment rates and associated renal outcomes have been suboptimal in this population. 10 Larger database studies are needed to understand the burden of anaemia and treatment patterns among patients with NDD-CKD, which would enable a more complete understanding of outcomes in this population and facilitate more robust economic modelling studies. The purpose of this study was to evaluate clinical characteristics, treatment patterns, and healthcare resource use (HCRU) and costs for patients in Japan with NDD-CKD and anaemia using real-world, longitudinal data.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A retrospective database analysis of erythropoiesis‐stimulating agent treatment patterns and associated healthcare resource use in patients with non–dialysis‐dependent chronic kidney disease–related anaemia in Japan

et al. 2023

View full text Add to dashboard Cite

Aim: This study was conducted to evaluate clinical characteristics, treatment patterns, and healthcare resource use (HCRU) for patients in Japan with non-dialysis-dependent chronic kidney disease (CKD) and anaemia. Methods: This retrospective, longitudinal, epidemiological database extraction study used the JMDC Claims Database, comprising 9.4 million unique beneficiaries. The observation period for anaemia and erythropoiesis-stimulating agent (ESA)/iron treatment was 1 January 2015 to 31 December 2018, and for HCRU and costs was 1 April 2016 to 31 March 2018. The non-dialysis-dependent CKD anaemia population, and the ESA treatment, iron treatment, and no-treatment cohorts were evaluated. Patient characteristics, treatment patterns, and outcomes were summarised descriptively. Results:The non-dialysis-dependent CKD anaemia population included 5908 patients (7.9%), with 464 patients in the ESA treatment cohort, 809 patients (13.7%) in the iron treatment cohort (13.7%), and 4405 (74.6%) patients in the no-treatment cohort. The prevalence of patients prescribed an antihypertensive, antidiabetic, and/or antihyperlipidaemic medication generally increased with increasing baseline CKD stage. Proportions of no treatment for anaemia decreased while ESA treatment increased with increasing CKD stage;ESA treatment increased with decreasing baseline haemoglobin levels. Patients in the ESA treatment cohort generally had more frequent events associated with HCRU and higher costs from HCRU-associated activities (e.g., inpatient and outpatient care, pharmacy). Conclusion:As CKD severity increased, anaemia management changed from iron use or no treatment to ESA use; however, anaemia may be undertreated across all CKD stages. ESA-treated patients incurred greater HCRU-associated costs relative to other patients with non-dialysis-dependent CKD anaemia in Japan.

show abstract

“…Investigations have found that at least 2.4 million people die each year from kidney disease, which is currently the 11 th leading cause of global mortality [ 2 , 3 ]. Hemodialysis therapy is a common technique in the treatment of kidney disease, which can replace the kidney to complete metabolic function in order to prolong survival [ 4 ]. Arteriovenous fistulas (AVFs) are the more important vascular access in hemodialysis, which have longer life and can ensure the smooth implementation of hemodialysis treatment and reduce the impact on the normal life of patients [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Application Value and Relevance Analysis of the Risk Evaluation System for Arteriovenous Fistula Puncture in Thrombosis after Puncture

Sun

2021

Journal of Healthcare Engineering

View full text Add to dashboard Cite

Objective. To analyze the application value and relevance of risk evaluation system for arteriovenous fistula (AVF) puncture in thrombosis after puncture. Methods. The clinical data of 180 patients treated with hemodialysis in the hemodialysis center of our hospital from November 2017 to November 2019 were retrospectively analyzed. After puncture, all patients received the digital subtraction angiography (DSA) examination, and based on whether they had AVF thrombosis, they were divided into the nonthrombosis group (n = 102) and thrombosis group (n = 78), and then, according to the parity of their admission numbers, the patients in the thrombosis group were subdivided into the study group (n = 39) and the reference group (n = 39), so as to analyze the risk factors of thrombosis after AVF puncture and the application value of the risk evaluation system for AVF puncture in preventing and treating thrombosis. Results. Compared with the reference group after intervention, the study group had significantly higher mean internal fistula blood flow volume ( P < 0.001) and significantly lower total incidence rate of vascular complications in fistulas ( P < 0.05); according to the multifactor binary logistic regression analysis, it was found that diabetes, systolic blood pressure reduction, hemoglobin, low-density lipoprotein cholesterol (LDL-C), ultrafiltration rate, and elevation of blood phosphorus and platelet levels were the risk factors of thrombosis after AVF puncture in hemodialysis patients. Conclusion. When risk factors of thrombosis are found in patients treated with hemodialysis, timely detection and intervention shall be applied in the early stage. Adopting the AVF puncture risk evaluation system has an extremely high application value in the clinic and is of important meaning in prolonging the service life of fistulas.

show abstract

Treatment for renal anemia and outcomes in non-dialysis patients with chronic kidney disease: the current status of regional medicine according to the Kyoto Fushimi Renal Anemia (KFRA) study

Cited by 5 publications

References 23 publications

Retrospective study on the effect of Niaoduqing particles on outcome of non-diabetic patients with stage IV chronic kidney disease

Retrospective study on the effect of Niaoduqing particles on outcome of non-diabetic patients with stage IV chronic kidney disease

A retrospective database analysis of erythropoiesis‐stimulating agent treatment patterns and associated healthcare resource use in patients with non–dialysis‐dependent chronic kidney disease–related anaemia in Japan

Application Value and Relevance Analysis of the Risk Evaluation System for Arteriovenous Fistula Puncture in Thrombosis after Puncture

Contact Info

Product

Resources

About